The Effect of Femoral Nerve Block on Postoperative Opioid Use After Anterior Cruciate Ligament (ACL) Reconstruction
NCT ID: NCT00175630
Last Updated: 2016-06-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
30 participants
INTERVENTIONAL
2010-12-31
2016-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Femoral Nerve Block for Analgesia After Anterior Cruciate Ligament Reconstruction
NCT01593566
Adductor Canal Block In Anterior Cruciate Ligament (ACL) Repair
NCT01791036
Comparing Adductor Canal Block and Adductor Canal Block-Local Infiltration Analgesia for Post-operative Pain Management
NCT04721119
Efficacy of Adductor Canal Block for Anterior Cruciate Ligament Surgery
NCT05532618
Effectiveness of Continuous Femoral Nerve Block Versus Single Shot Femoral Nerve Block for Pain Control
NCT01916590
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Administration of a femoral nerve block (bupivacaine HCL)
See Detailed Description
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Tolerance to bupivacaine
* Tolerance to non-steroidal anti-inflammatory drugs (NSAIDs)
* Informed consent
Exclusion Criteria
* Complex associated injuries or pre-existing conditions that will delay time to ambulation
* Children with tibial avulsion fractures
* Allergic and/or sensitive to bupivacaine and/or NSAIDs
* 30% over ideal body weight
* Acute ACL reconstruction (done less than 2 weeks after injury)
* Pre-existing femoral nerve injury
* Psychiatric patients on psychotropic agents
* History of drug or alcohol dependence or recreational drug use
* Refusal to provide informed consent
12 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of British Columbia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christopher Reilly, MD
Role: PRINCIPAL_INVESTIGATOR
University of British Columbia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
British Columbia Children's Hospital, Department of Orthopaedics
Vancouver, British Columbia, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
W05-0024
Identifier Type: -
Identifier Source: secondary_id
H05-70078
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.